Lu Kang Pharmaceuticals (600789.SH) and its holding subsidiary have been selected for the eleventh batch of national drug procurement for multiple products.

CapitalVue Finance News: Shandong Lukang Pharmaceutical (600789.SH) announced that the company and its controlling subsidiary Shandong Lukang Pharmaceutical Group Sate Co., Ltd. (referred to as "Sate Company") part of the drugs were selected for this centralized procurement. The selected products include: Cefoperazone Sodium for Injection, Dapagliflozin Tablets, Adenosine Cobamamide Capsules, and Methylprednisolone Sodium Succinate for Injection. The total sales of the selected products in 2024 amounted to 405 million yuan.